Loading
Guidelines usually wait for a drug to be licensed for a use before recommending it. For old drugs no one will license, guidelines should act directly on trial evidence.
Guideline bodies (NCCN, ESMO, NICE) do recommend off-label uses but often slowly and inconsistently for interventions without a sponsor to submit evidence. The proposal is a standing fast-track procedure in major guideline organisations, triggered automatically by publication of a registration-quality randomised trial of an off-patent drug, with a decision within six months, an explicit statement of the recommendation's reimbursement implications, and a mechanism for payers to adopt it in the absence of a label.
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS, European Society for Medical Oncology (ESMO), Knowledge reaches practice too slowly.
Shares NCCN Guidelines, American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
Shares NCCN Guidelines, European Society for Medical Oncology (ESMO), Knowledge reaches practice too slowly.
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS, American Society of Clinical Oncology (ASCO).
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.